Rheumatoid Arthritis Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Global Rheumatoid Arthritis Drugs Market is segmented by Type of Molecule (Pharmaceuticals and Biopharmaceuticals), Drug Class, Sales Channel, and Geography.

Market Snapshot

rheumatoid arthritis market trends
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 10.5 %
rheumatoid arthritis market size

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The key factors propelling the growth of the rheumatoid arthritis drugs market are the launch of new biosimilars, rising prevalence of arthritis, and an increase in the acceptance of biopharmaceuticals.

The major factors that fuel the growth of the market are the growing burden of rheumatoid arthritis disease with the increasing geriatric population. It usually affects the geriatric population, and the prevalence is seen higher in females as compared to males. Therefore, larger cases of this disease can be found in aged population reaching hospitals.

There are also several therapeutics and medications that have been developed in the recent years, to treat the symptoms of rheumatoid arthritis. Rheumatoid arthritis drugs management is generally associated with a high cost. Most commonly used drugs are disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic drugs. The biologics account for a prominent market share, in terms of revenue, due to the considerably high cost of these medicines. However the costs of rheumatoid arthritis drugs and NSAIDs are less than biologics. Thus, growing availability and awareness of safer drugs are anticipated to increase the global rheumatoid arthritis drugs market.

Scope of the Report

As per the scope of the report, rheumatoid arthritis is an autoimmune disorder that causes pain and inflammation in the joints of the body. Rheumatoid arthritis disease mostly affects the joints of the hand, wrists, elbows, knees, and ankles. It also affects the cardiac and respiratory system, and is known as systemic disease. It thus exhibits symptoms of swelling, redness, and warmth in the affected areas. Owing to the rise in the adoption of the sedentary lifestyle, the patient pool is expected to witness a healthy growth.

By Type of Molecule
Pharmaceuticals
Biopharmaceuticals
By Drug Class
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Analgesics
Other Drug Classes
By Sales Channel
Prescription
Over-the-counter (OTC)
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East & Africa
GCC
South Africa
Rest of Middle-East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

NSAIDs, by Drug Class is Expected to be the Largest Segment Over the Forecast Period

NSAIDs are being widely utilized for the symptomatic treatment of rheumatic disorders. Disease-modifying anti-rheumatic drugs (DMARDs) are also considered as the gold standard for the treatment of moderate to severe rheumatoid arthritis. Unlike conventional DMARDs, the NSAIDs give symptomatic relief, biologic drugs are more efficient in the management of rheumatoid arthritis.

The increasing prevalence of the disease globally is boosting the segment growth. With the growing number of arthritis cases, the use of NSAIDs and their production is expected to observe healthy demand and supply throughout the forecast period. As per a 2017 publication in Morbidity and Mortality Weekly Report, by 2040, an estimated 78 million (26% United States adults aged 18 years or older are projected to have doctor-diagnosed arthritis. This shows a steady growth in arthritic cases, supporting the expected growth of NSAIDs in the market.

rheumatoid arthritis market growth

Asia-Pacific is Witnessing High Growth and is Expected to Follow the Same Trend Over the Forecast Period

The Asia-Pacific market is projected to witness high growth during the forecast period, due to increasing healthcare expenditure. Moreover, the low cost of manufacturing in China and India has resulted in the rise in the production facilities, attracting pharmaceutical and biotechnological giants to the Asia-Pacific region from across the world.

The increase in the incidence of rheumatoid arthritis disease is also expected to fuel the market in the region during the forecast period. For instance, as per the Institute for Health Metrics and Evaluation, the number of cases of rheumatoid arthritis has increased from 183,272 in 2007 to 263,365 in 2017 only in India. Therefore, analyzing the number of cases in other major countries of the Asia Pacific region, the healthcare activities in relation to the treatment of rheumatoid arthritis would require large and continuous support from everyone. 

 rheumatoid arthritis market share

Competitive Landscape

A majority of rheumatoid arthritis drug products are being manufactured by key players. The market leaders in this industry have established their position in the market, and these manufacturers have a wide product range to offer and have an extensive distribution system across the world. Additionally, the emerging markets in the Asia-Pacific region are witnessing the entry of small players.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Preference Towards Development of Biologics and Biosimilars

      2. 4.2.2 Rising Burden of Arthritis

    3. 4.3 Market Restraints

      1. 4.3.1 Patent Expiration of Blockbuster Drugs

      2. 4.3.2 Alternative Treatment Options

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type of Molecule

      1. 5.1.1 Pharmaceuticals

      2. 5.1.2 Biopharmaceuticals

    2. 5.2 By Drug Class

      1. 5.2.1 Non-steroidal Anti-inflammatory Drugs (NSAIDs)

      2. 5.2.2 Corticosteroids

      3. 5.2.3 Analgesics

      4. 5.2.4 Other Drug Classes

    3. 5.3 By Sales Channel

      1. 5.3.1 Prescription

      2. 5.3.2 Over-the-counter (OTC)

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East & Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East & Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Amgen Inc.

      3. 6.1.3 Bayer AG

      4. 6.1.4 Boehringer Ingelheim GmbH

      5. 6.1.5 Bristol-Myers Squibb Company

      6. 6.1.6 Celgene Corporation

      7. 6.1.7 F. Hoffmann-La Roche AG

      8. 6.1.8 Johnson & Johnson

      9. 6.1.9 Merck & Co. Inc.

      10. 6.1.10 Novartis AG

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Rheumatoid Arthritis Drugs Market market is studied from 2018 - 2026.

The Rheumatoid Arthritis Drugs Market is growing at a CAGR of 10.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

AbbVie Inc., Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company are the major companies operating in Rheumatoid Arthritis Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!